MedTrace Logo

Approaches to Identify Early Biomarkers and Pathogenesis of Anthracycline Cardiotoxicity

NCT04036045 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2025-10-06

No results posted yet for this study

Summary

Early microRNAs (miRs) and Cardiac Magnetic Resonance (CMR)-derived strain analysis and detection of genes contributing to Anthracycline-Induced Cardiotoxicity (AIC) sensitivity and resistance will identify pediatric cancer patients most and least likely to develop AIC.

Conditions

  • Childhood Cancer

Interventions

OTHER

Cardiac MRI

Patients will have a cardiac MRI at four time points during the study

OTHER

Echocardiogram

Patients will have an echocardiogram at four time points during the study

OTHER

Blood Draw

Patients will have blood drawn at four time points to analyze micro RNAs and Biomarkers before, during and after anthracycline treatment. Patients will also have one blood draw for future genetic sequencing.

Sponsors & Collaborators

  • Nationwide Children's Hospital

    collaborator OTHER

  • Connecticut Children's Medical Center

    lead OTHER

Principal Investigators

  • Olga Salazar, MD · Connecticut Children's Medical Center

Eligibility

Min Age
9 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-12
Primary Completion
2024-12-31
Completion
2025-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04036045 on ClinicalTrials.gov